康美藥業(600518.SH):關聯方廣藥集團將成爲公司新的債權人及孫公司抵押權人
格隆匯7月4日丨康美藥業(600518.SH)公佈,康美藥業與廣州資產存在歷史債務糾紛,公司全資孫公司成都康美對前述4,939.11萬元債務提供抵押擔保。廣東省高級人民法院於2023年11月作出(2022)粵民終3992號《民事判決書》,成都康美需對康美藥業所負前述債務承擔抵押責任,後廣州資產向法院申請強制執行。近期,廣州資產在阿里平臺公開拍賣前述債權,爲協助公司化解歷史債務問題,保障孫公司正常生產經營,公司關聯方廣藥集團近日通過公開競買方式以4,350萬元取得該筆債權及其從屬的抵押權。本次債權交易雙方主體爲廣州資產與廣藥集團,公司及孫公司無需履行內部審議程序。交易完成後,關聯方廣藥集團將成爲公司新的債權人及孫公司抵押權人,該交易被動形成關聯交易。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.